Clinical trials for Different Types of Cancer

Paid Clinical Trials and Focus Groups


Find Paid Clinical Trials

Paid Clinical Trials - : Cancers

Top of Directory » All Categories » by Illness » Cancers



  • Trial of Gemcitabine With or Without AS703026 (MSC1936369B) in Pancreas Cancer

    Condition:   Pancreatic Adenocarcinoma
    Interventions:   Drug: MEK Inhibitor AS703026;   Drug: Gemcitabine and Placebo;   Drug: Gemcitabine and MEK Inhibitor AS703026
    Sponsor:   EMD Serono
    Recruiting - verified November 2009
  • Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

    Condition:   Advanced Gastric Cancer
    Interventions:   Drug: Paclitaxel;   Drug: capecitabine;   Drug: capecitabine;   Drug: cisplatin
    Sponsors:   Peking University;   Roche Pharma AG
    Recruiting - verified November 2009
  • Lung Cancer Mutation Consortium Protocol

    Condition:   Stage IIIB/IV Adenocarcinoma
    Intervention:   Other: No intervention
    Sponsors:   University of Colorado at Denver and Health Sciences Center;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By Chemotherapy With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery

    Condition:   Pancreatic Cancer
    Interventions:   Drug: capecitabine;   Drug: erlotinib hydrochloride;   Drug: fluorouracil;   Drug: gemcitabine hydrochloride;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
    Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
    Not yet recruiting - verified November 2009
  • Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

    Condition:   Lung Cancer
    Interventions:   Biological: Seneca Valley virus-001;   Other: placebo
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Not yet recruiting - verified November 2009
  • Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

    Condition:   Liver Cancer
    Interventions:   Drug: doxorubicin hydrochloride;   Drug: sorafenib tosylate
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Not yet recruiting - verified November 2009
  • Single-arm Study of Photodynamic Laser Therapy Using Foscan for Non-curatively-resectable Bile Duct Carcinoma

    Condition:   Non-curative Resectable Bile Duct Carcinoma
    Intervention:   Drug: Temoporfin
    Sponsors:   University of Salzburg;   Biolitec Pharma ltd., United Drug House, Magna Drive,Dublin 24,Irland
    Recruiting - verified November 2009
  • A Phase II Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts

    Condition:   Adenocarcinoma of Gall Bladder or Biliary Ducts
    Intervention:   Drug: Gemcitabine, Capecitabine and Bevacizumab
    Sponsor:   Roswell Park Cancer Institute
    Not yet recruiting - verified November 2009
  • A Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma

    Conditions:   Carcinoma, Renal Cell;   Lymphoma, Non-Hodgkin
    Intervention:   Drug: SGN-75
    Sponsor:   Seattle Genetics, Inc.
    Recruiting - verified November 2009
  • Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma

    Condition:   Prostate Cancer
    Interventions:   Drug: cyproterone acetate;   Drug: Venlafaxine;   Drug: -Medroxyprogesterone
    Sponsor:   Laboratoires Takeda
    Completed - verified November 2009
  • Merkel Positron Emission Tomography (PET) Protocol

    Condition:   Stage I or II Merkel Cell Cancer of the Skin
    Interventions:   Drug: Carboplatin;   Drug: Etoposide;   Radiation: Radiotherapy
    Sponsor:   Trans-Tasman Radiation Oncology Group (TROG)
    Not yet recruiting - verified November 2009
  • A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect)

    Conditions:   Renal Cell Carcinoma;   Cardiotoxicity;   Heart Failure;   Hypertension
    Intervention:  
    Sponsor:   University of Alberta
    Not yet recruiting - verified November 2009
  • Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

    Conditions:   Breast Cancer;   Lung Cancer;   Colon Cancer;   Pancreatic Cancer;   Head and Neck Cancer;   Kidney Cancer;   Sarcoma;   Hepatocellular Cancer
    Interventions:   Drug: Pazopanib;   Drug: Pazopanib;   Drug: Ixabepilone;   Drug: Ixabepilone;   Drug: Ixabepilone
    Sponsors:   Masonic Cancer Center, University of Minnesota;   GlaxoSmithKline;   Bristol-Myers Squibb
    Recruiting - verified November 2009
  • Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor

    Conditions:   Endometrial Cancer;   Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Liver Cancer;   Lung Cancer;   Ovarian Cancer
    Interventions:   Biological: bevacizumab;   Drug: temsirolimus;   Other: laboratory biomarker analysis
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Not yet recruiting - verified November 2009
  • Percutaneous Renal Tumor Cryoablation Followed by Biopsy

    Condition:   Renal Cancer
    Intervention:   Procedure: percutaneous cryoablation
    Sponsor:   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified November 2009
  • Temsirolimus and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer and Liver Dysfunction

    Conditions:   Hepatic Complications;   Liver Cancer
    Interventions:   Drug: sorafenib tosylate;   Drug: temsirolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   UCSF Helen Diller Family Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting - verified November 2009
  • Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

    Condition:   Liver Cancer
    Interventions:   Drug: doxorubicin hydrochloride;   Drug: mitomycin C;   Drug: sorafenib tosylate;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • Regulatory Post Marketing Surveillance Study on Nexavar®

    Conditions:   Carcinoma, Hepatocellular;   Carcinoma, Renal Cell
    Intervention:   Drug: Sorafenib ( Nexavar, BAY43-9006)
    Sponsor:   Bayer
    Recruiting - verified November 2009
  • Erlotinib Hydrochloride in Treating Patients With Previously Treated Non-Small Cell Lung Cancer, Head and Neck Cancer, or Esophageal Cancer and Precancerous Lesions of the Lung

    Conditions:   Cancer Survivor;   Esophageal Cancer;   Head and Neck Cancer;   Lung Cancer;   Precancerous/Nonmalignant Condition
    Interventions:   Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: pharmacological study
    Sponsors:   Robert H. Lurie Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • AZD6244 in Treating Patients With Recurrent or Persistent Endometrial Cancer

    Condition:   Endometrial Cancer
    Interventions:   Drug: MEK inhibitor AZD6244;   Other: laboratory biomarker analysis
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery

    Conditions:   Colorectal Cancer;   Precancerous/Nonmalignant Condition
    Interventions:   Drug: rosuvastatin;   Other: placebo
    Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
    Not yet recruiting - verified November 2009
  • BIBW 2992 as a Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor [EGFR]

    Condition:   Carcinoma, Non-Small-Cell Lung
    Intervention:   Drug: BIBW 2992
    Sponsor:   Boehringer Ingelheim Pharmaceuticals
    Not yet recruiting - verified October 2009
  • Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer

    Condition:   Liver Cancer
    Interventions:   Drug: doxorubicin-eluting beads;   Drug: everolimus;   Other: placebo
    Sponsor:   Swiss Group for Clinical Cancer Research
    Not yet recruiting - verified November 2009
  • Extension Study of EC145 for Subjects Enrolled in a Previous Study With EC145

    Condition:   Adenocarcinoma of the Lung
    Intervention:   Drug: EC145
    Sponsor:   Endocyte
    Not yet recruiting - verified October 2009
  • Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer

    Condition:   Liver Cancer
    Interventions:   Biological: cixutumumab;   Drug: sorafenib tosylate;   Other: laboratory biomarker analysis
    Sponsors:   California Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Multipolar Radiofrequency Ablation for Hepatocellular Carcinoma Using Extra Nodular Versus Intranodular Technique

    Condition:   Hepatocellular Carcinomas
    Intervention:   Procedure: Radiofrequency ablation
    Sponsor:   Assistance Publique - Hôpitaux de Paris
    Not yet recruiting - verified November 2009
  • Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer

    Condition:   Advanced Pancreatic Cancer
    Interventions:   Drug: erlotinib;   Drug: Gemcitabine;   Drug: Nab-paclitaxel
    Sponsor:   OSI Pharmaceuticals
    Not yet recruiting - verified November 2009
  • Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma

    Conditions:   Hepatocellular Carcinoma;   Hepatitis C Virus Chronic Infection
    Intervention:   Biological: CP 675,206
    Sponsors:   Instituto Cientifico y Tecnologico de Navarra, Universidad de Navarra;   Pfizer
    Recruiting - verified November 2009
  • Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma

    Conditions:   Chronic Hepatitis C;   Neoplasms
    Intervention:   Drug: Peginterferon alfa-2a plus ribavirn
    Sponsor:   Kaohsiung Medical University
    Active, not recruiting - verified November 2009
  • Guided Biopsy for Mapping Prostate Cancer

    Condition:   Prostate Cancer
    Intervention:   Procedure: Prostatectomy
    Sponsor:   Roswell Park Cancer Institute
    Not yet recruiting - verified November 2009
  • Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma

    Condition:   Hepatocellular Carcinoma
    Intervention:   Drug: sorafenib with temsirolimus
    Sponsors:   University of California, San Francisco;   Northwestern University
    Not yet recruiting - verified November 2009
  • Study of Panobinostat in Combination With Sorafenib in Kidney or Lung Cancers

    Conditions:   Renal Cancer;   Non Small Cell Lung Cancer (NSCLC)
    Intervention:   Drug: Panobinostat (LBH589), Sorafenib
    Sponsors:   Medical University of South Carolina;   Novartis Pharmaceuticals
    Recruiting - verified November 2009
  • Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma

    Conditions:   Hepatocellular Carcinoma;   Liver Cancer
    Interventions:   Drug: Sorafenib;   Radiation: Stereotactic Body Radiotherapy (SBRT)
    Sponsors:   University of Alabama at Birmingham;   Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
    Not yet recruiting - verified November 2009
  • Biomarkers in Tumor Tissue Samples From Young Patients With Very Low Risk Wilms Tumors

    Condition:   Kidney Cancer
    Interventions:   Genetic: DNA methylation analysis;   Genetic: gene expression analysis;   Genetic: loss of heterozygosity analysis;   Genetic: microarray analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting - verified October 2009
  • Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer

    Condition:   Liver Cancer
    Interventions:   Drug: everolimus;   Drug: sorafenib tosylate;   Other: questionnaire administration;   Procedure: quality-of-life assessment
    Sponsor:   Swiss Group for Clinical Cancer Research
    Not yet recruiting - verified November 2009
  • Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

    Condition:   Liver Cancer
    Interventions:   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: mitomycin C;   Drug: sorafenib tosylate;   Other: placebo
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Not yet recruiting - verified November 2009
  • Novel Prognostic Markers in Renal Cancer

    Condition:   Renal Cell Carcinoma
    Intervention:  
    Sponsor:   Royal Marsden NHS Foundation Trust
    Recruiting - verified October 2009
  • Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer

    Condition:   Endometrial Cancer
    Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel;   Procedure: adjuvant therapy;   Radiation: intensity-modulated radiation therapy
    Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
    Not yet recruiting - verified October 2009
  • Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver Cancer

    Condition:   Hepatocellular Carcinoma
    Intervention:   Drug: Sorafenib
    Sponsor:   Fudan University
    Recruiting - verified October 2009
    • Menu
    Find Paid Clinical Trials